Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. Oktober 2019 07:09 ET | Quelle: Genmab A/S

CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma

Company Announcement CHMP issued a positive opinion for DARZALEX® in combination with lenalidomide and dexamethasone as treatment for newly diagnosed adult patients with multiple myeloma who are...
15. Oktober 2019 06:47 ET | Quelle: Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2019

Company Announcement Net sales of DARZALEX in the third quarter of 2019 totaled USD 765 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark;...
11. Oktober 2019 14:55 ET | Quelle: Genmab A/S

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement Copenhagen, Denmark; October 11, 2019 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 17,653 restricted stock units and 62,848...
01. Oktober 2019 14:14 ET | Quelle: Genmab A/S

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement Copenhagen, Denmark; October 1, 2019 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 28,719 shares as a consequence of the exercise of employee warrants. The...
26. September 2019 11:43 ET | Quelle: Genmab A/S

Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma

Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with bortezomib, thalidomide (an immunomodulatory agent) and dexamethasone as treatment for patients newly diagnosed...
13. September 2019 09:40 ET | Quelle: Genmab A/S

Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Company Announcement Phase III CANDOR study of daratumumab in combination with carfilzomib and dexamethasone in relapsed or refractory multiple myeloma met the primary endpoint of improvement in...
13. September 2019 09:04 ET | Quelle: Genmab A/S

Detailed Results from the Phase III ASCLEPIOS I & II Studies of Ofatumumab in Patients with Relapsing Multiple Sclerosis Presented at ECTRIMS

Company Announcement Details from the ASCLEPIOS I & II studies of subcutaneous ofatumumab (OMB157) versus teriflunomide in patients with relapsing multiple sclerosis (RMS) were presented at the...
09. September 2019 09:07 ET | Quelle: Genmab A/S

Genmab and Tempus Enter into Strategic Collaboration Agreement

Media Release Copenhagen, Denmark, September 9, 2019 Genmab and Tempus sign agreement to research and develop novel targets Genmab A/S (Nasdaq: GMAB) announced today that it has entered into a...
30. August 2019 01:16 ET | Quelle: Genmab A/S

Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis Studies

Company Announcement In ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoints to reduce the annualized relapse rate (ARR) over teriflunomide in patients with relapsing forms of multiple...
22. August 2019 01:10 ET | Quelle: Genmab A/S

Genmab Announces Approval of DARZALEX® (daratumumab) in Frontline Multiple Myeloma in Japan

Company Announcement DARZALEX® approved in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma ineligible for autologous stem...

Vorherige Seite

Nächste Seite